Pediatrics
Showing 481-500 of 1,612 Results
-
Chris Garcia
Younger Family Professor and Professor of Structural Biology
Current Research and Scholarly InterestsStructural and functional studies of transmembrane receptor interactions with their ligands in systems relevant to human health and disease - primarily in immunity, infection, and neurobiology. We study these problems using protein engineering, structural, biochemical, and combinatorial biology approaches.
-
Manuel Garcia-Careaga
Current Research and Scholarly InterestsGastroenterology, liver disease in cystic fibrosis patients, percutaneous gastrostomy tube in pediatric population, inflamatory bowel disease, failure to thrive
-
Christopher Gardner
Rehnborg Farquhar Professor
Current Research and Scholarly InterestsThe role of nutrition in individual and societal health, with particular interests in: plant-based diets, differential response to low-carb vs. low-fat weight loss diets by insulin resistance status, chronic disease prevention, randomized controlled trials, human nutrition, community based studies, Community Based Participatory Research, sustainable food movement (animal rights and welfare, global warming, human labor practices), stealth health, nutrition policy, nutrition guidelines
-
Brice Gaudilliere
Professor of Anesthesiology, Perioperative and Pain Medicine (MSD) and, by courtesy, of Pediatrics (Neonatology)
Current Research and Scholarly InterestsThe advent of high dimensional flow cytometry has revolutionized our ability to study and visualize the human immune system. Our group combines high parameter mass cytometry (a.k.a Cytometry by Time of Flight Mass Spectrometry, CyTOF), with advanced bio-computational methods to study how the human immune system responds and adapts to acute physiological perturbations. The laboratory currently focuses on two clinical scenarios: surgical trauma and pregnancy.
-
Charles Gawad
Associate Professor of Pediatrics (Hematology/Oncology)
BioOur lab works at the interface of biotechnology, computational biology, cellular biology, and clinical medicine to develop and apply new tools for characterizing genetic variation across single cells within a tissue with unparalleled sensitivity and accuracy. We are focused on applying these technologies to study cancer clonal evolution while patients are undergoing treatment with the aim of identifying cancer clonotypes that are associated with resistance to specific drugs so as to better understand and predict treatment response. We are also applying these methods to understand how more virulent pathogens emerge from a population of bacteria or viruses with an emphasis on developing a deeper understanding of how antibiotic resistance develops.
-
Benedikt Geier
Postdoctoral Scholar, Infectious Diseases
BioB.Sc. Biology, Ludwig Maximilian University (LMU), Munich/Germany (2013)
M.Sc. Biology and bioimaging, Ludwig Maximilian University (LMU), Munich/Germany (2015)
Ph.D., Animal-Microbe Symbioses, Max Planck Institute for Marine Microbiology in Bremen/Germany (2020)
Benedikt joined the Amieva Lab from Germany in 2022. During his B.Sc. and M.Sc. programs in zoology, he became fascinated with 3D imaging approaches to study small animal microanatomy. He spent his PhD developing in situ imaging approaches to study deep-sea symbioses and fell in love with studying host-microbe interactions. In the Amieva Lab, Benedikt will advance his previously developed correlative chemical imaging techniques to resolve metabolic and cellular interactions that drive H. pylori pathogenesis in the gastric glands.
More about Benedikt's transition from deep-sea microbiology into infectious disease research can be found here:
https://scopeblog.stanford.edu/2022/08/24/unconventional-paths-deep-sea-to-the-stomach/ -
Yael Gernez
Clinical Associate Professor, Pediatrics - Immunology
BioMy clinic focuses on solving the molecular puzzles that underlie rare allergic and immunologic diseases to shed light on fundamental principles governing allergy, inflammation and immune system defects. My goal is to find better and safer therapies for my patients with rare diseases that include autoinflammation, autoimmunity and primary immune deficiency. It is important to highlight that every patient requires individualized therapeutic approaches based on their underlying genetic problem and the types and severity of their clinical manifestations. For some patients, a hematopoietic stem cell transplant (HSCT) is curative while for others, a targeted drug therapy, such as a biologic or small molecule agent, is most suitable. In some cases, a truly novel therapy may be required, .e.g., anti-sense oligonucleotide therapy to suppress aberrant gene splicing or adoptive cellular therapy. My passion is to provide the best personalized therapy for our patients with allergy and immunology diseases. This often requires performing very specialized functional assays and in some cases in enlisting laboratories with specific expertise or interest in particular genetic disorders.
-
Zahra Ghazi-Askar
Clinical Associate Professor, Emergency Medicine
Clinical Associate Professor, PediatricsBioDr. Ghazi-Askar is Assistant Professor of Emergency Medicine and, by courtesy, of Pediatrics and serves as the Director of Pediatric Ultrasound Education in the Department of Emergency Medicine . As an academic clinical educator in with expertise in pediatric and adult point-of-care ultrasound, Dr. Ghazi-Askar's clinical focus is on children and young adults who seek care in the pediatric emergency department. She is specialty-board certified in pediatric emergency medicine.
At a national level, Dr. Ghazi-Askar is the Chair of Point-of-Care Ultrasound subcommittee for the Association of Pediatric Program Directors (APPD), where she is leading the development of an educational curriculum for pediatric residency point-of-care ultrasound.
Dr. Ghazi-Askar also has expertise in the field of Tele-ultrasound, where she is able to teach point-of-care ultrasound virtually where clinical expertise may otherwise not be available. Here she is able to provide education and health equity when it is most needed.
